Pharmamarketeer

Pfizer’s Xeljanz jumps into ulcerative colitis fray with best-case FDA approval

Xeljanz is on a roll. The Pfizer immunology blockbuster scored a big new approval in psoriatic arthritis last year, and now it has won an FDA green light to treat ulcerative colitis. Plus, the approval includes the larger 10 mg dose, despite some internal agency questions about safety.

Reageer

Medhc-fases-banner
Advertentie(s)